Terms: = Ovarian cancer AND AKT2, PKBBETA, 208, ENSG00000105221, RAC-BETA, P31751, PRKBB AND Clinical Outcome
4 results:
1. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy.
Feng H; Qiu L; Shi Z; Sheng Y; Zhao P; Zhou D; Li F; Yu H; You Y; Wang H; Li M; Zhu S; Du Y; Cui J; Sun J; Liu Y; Jiang H; Wu X
Cancer Med; 2023 Feb; 12(3):3313-3327. PubMed ID: 36028997
[TBL] [Abstract] [Full Text] [Related]
2. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer.
Chen J; Kang S; Wu J; Zhao J; Si W; Sun H; Li Y
J Obstet Gynaecol Res; 2022 May; 48(5):1240-1247. PubMed ID: 35150042
[TBL] [Abstract] [Full Text] [Related]
3. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
4. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract] [Full Text] [Related]
